Gynecologic Cancer
From the Journals
Third COVID booster benefits cancer patients
For the first time, researchers have quantified the benefits of boosters for COVID-19 in cancer patients.
Latest News
HPV vaccine effectiveness dependent on age at receipt
HPV vaccination does not have any therapeutic effect on HPV infections already acquired, which is likely to explain the difference in infection...
Latest News
Study uncovers two molecular subgroups of cervical cancer
Patients with so-called C2 tumors were more than twice as likely to die from their cervical cancer at any point during the follow-up period - up...
Feature
Hair straighteners’ risk too small for docs to advise against their use
Primary care doctors are unlikely to address the increased risk of uterine cancer in women who frequently use hair straighteners that a new study...
Opinion
Germline genetic testing: Why it matters and where we are failing
Cancer and medical societies recommend universal genetic counseling and testing for patients diagnosed with epithelial ovarian cancer.
Latest News
HPV infection in pregnancy higher among women living with HIV
"Women living with HIV have a sixfold increased rate of developing cervical cancer compared to women without HIV."
Diminutio
Cancer as a full contact sport
The complexity of cancer care has long necessitated a team approach to planning cancer treatment.
Opinion
The role of repeat uterine curettage in postmolar gestational trophoblastic neoplasia
Second uterine evacuation for treatment of nonmetastatic, low-risk postmolar GTN is a reasonable treatment option and one that should be...
Conference Coverage
High BMI linked to better survival for cancer patients treated with ICI, but for men only
The reasons behind the findings and implications for treatment are unknown, as is whether it applies to patients with specific cancers.
From the Journals
Early trial supports hypofractionated radiotherapy in uterine cancer
Early toxicity results are encouraging, but long-term efficacy and safety remain unknown.
Conference Coverage
A farewell to arms? Drug approvals based on single-arm trials can be flawed
Objective responses, not time-dependent survival outcomes, should be endpoints for single-arm trials, with results only used for conditional...